We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PCR Market Rises to USD3.5 Billion for 2015

By LabMedica International staff writers
Posted on 04 Jul 2016
The total PCR (polymerase chain reaction) technologies market was valued at about USD3.5 billion for 2015, up from USD3.2 billion in 2013, according to Kalorama Information (New York, NY, USA), a healthcare market research company.

PCR is a biochemical technology in molecular biology that is used to amplify a single copy or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. More...
PCR technologies are being increasingly used for medical testing, particularly for diagnosing bacterial and infectious diseases, detecting antibiotic resistance, and for cancer exploration of mutations and detection of genetic abnormalities. These technologies, particularly quantitative PCR (qPCR) and digital PCR (dPCR), hold great promise for expanding diagnostic applications.

qPCR is mainly used for DNA sequencing and gene expression in stem cell research, oncology and genetic disease research, pathogen detection and infectious disease research, and plant sciences research. It is also utilized in forensic science, food and safety applications, genetically modified organisms (GMO) testing, and detection of genetic abnormalities and cancer mutations. The coming years are expected to witness an expansion in qPCR-based diagnostic tests.

On the other hand, dPCR provides absolute measurement of copies and is the next logical step in PCR evolution. dPCR partitions sample and reaction components into hundreds or thousands of reaction chambers to count the presence or absence of molecules. The technology provides greatly improved sensitivity in the detection of rare mutations and sequences, and is likely to become increasingly important with the evolution of clinical applications.

“qPCR has established itself as the workhorse in the research laboratory,” said Bruce Carlson, Publisher of Kalorama Information. “But dPCR’s potential is greater in diagnostic applications due to its sensitivity, precision, robustness, and reproducibility.”

The US and European PCR technology markets have been witnessing intensifying competition, resulting in increasing participation in other regions like Asia and Latin America. Among the number of companies in the PCR technology market are large multi-product companies like Thermo Fisher Scientific (Waltham, MA, USA), Roche Holding AG (Basel, Switzerland), and Abbott (Abbot Park, IL, USA), as well as small niche developers such as RainDance Technologies (Billerica, MA, USA).

Related Links:
Kalorama Information
Thermo Fisher Scientific
Roche
Abbott
RainDance Technologies

New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.